Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs
Why the study?
Limited data exist on direct-acting oral anticoagulants in morbidly obese patients with venous thromboembolism.
Does rivaroxaban compared to warfarin improve clinical and economic outcomes in morbidly obese patients with venous thromboembolism?
Structured PICO
Does rivaroxaban compared to warfarin improve clinical and economic outcomes in morbidly obese patients with venous thromboembolism?
P
Population
5,780 morbidly obese patients with venous thromboembolism (2,890 matched pairs) from 2 US claims databases
I
Intervention
Rivaroxaban
C
Comparator
Warfarin
O
Outcome
Recurrent VTE and major bleedinghard clinical
In morbidly obese patients with VTE, rivaroxaban is associated with similar efficacy and safety compared to warfarin, but with lower healthcare resource utilization and medical costs.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Rivaroxaban showed similar recurrent VTE and major bleeding risks versus warfarin; leaves open need for randomized confirmation in morbid obesity.
Cite This Study
Spyropoulos et al. (2019) studied this question.